Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy
Author(s) -
Thomas S. Uldrick,
Scott V. Adams,
Rémi Fromentin,
Michael Roche,
Steven P. Fling,
Priscila Gonçalves,
Kathryn Lurain,
Ramya Ramaswami,
Chia-Ching Jackie Wang,
Robert J. Gorelick,
Jorden L. Welker,
Liz O’Donoghue,
Harleen Choudhary,
Jeffrey D. Lifson,
Thomas A. Rasmussen,
Ajantha Rhodes,
Carolin Tumpach,
Robert Yarchoan,
Frank Maldarelli,
Martin A. Cheever,
RafickPierre Sékaly,
Nicolas Chomont,
Steven G. Deeks,
Sharon R. Lewin
Publication year - 2022
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.abl3836
Subject(s) - viremia , pembrolizumab , virology , medicine , antibody , human immunodeficiency virus (hiv) , reverse transcriptase , rna , in vivo , immunology , immune system , biology , immunotherapy , gene , biochemistry , microbiology and biotechnology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom